Search clinical trials for: Aflibercept 40 MG/ML Intraocular Solution [EYLEA]

Total 498 results

Bernardete Pessoa MD

Completed

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema (SWITCH)

Diabetic Retinopathy | Diabetic Macular Edema
Faculty Hospital Kralovske Vinohrady

Withdrawn

Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation (BEY-RAP)

Wet Macular Degeneration

Czechia
Sandoz

Completed

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration (Mylight)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, Czechia, Australia, Austria, France, Germany, Hungary, Israel, Japan, Latvia, Lithuania, Poland, Portugal, Slovakia, Spain
Medical University of Graz

Active, not recruiting

Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration (FAN)

Neovascular Age-related Macular Degeneration

Austria
Uptown Eye Specialists

Unknown

Diabetic Macular Edema - Obstructive Sleep Apnea Relationship Study (DME-OSA)

Diabetic Macular Edema | Sleep Apnea | Non Proliferative Diabetic Retinopathy

Canada
Universitair Ziekenhuis Brussel

Active, not recruiting

Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma (GlitIpNi)

Glioblastoma

Belgium
Chiang Mai University

Recruiting

Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept

Polypoidal Choroidal Vasculopathy

Thailand
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Unknown

Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients (INHIXACOV19)

COVID-19

Italy
Sandoz

Completed

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

Neovascular Age-related Macular Degeneration (nAMD)

United States
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
UroGen Pharma Ltd.

Completed

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

Neoplasms | Urologic Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms

India
Bayer
Regeneron Pharmaceuticals

Not yet recruiting

A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (PHOTONiC)

Diabetic Macular Edema
University of North Carolina, Chapel Hill
AbbVie

Completed

Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

Psoriasis

United States
Alcon Research

Completed

Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 (HARRIER)

Choroidal Neovascularization | Neovascular Age-Related Macular Degeneration
Alcon Research

Completed

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 (HAWK)

Choroidal Neovascularization | Neovascular Age-Related Macular Degeneration

United States
Novo Nordisk A/S

Completed

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Non-alcoholic Steatohepatitis

Canada
Kadmon Corporation, LLC
Quotient Sciences

Completed

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Healthy Volunteers

United Kingdom
Regeneron Pharmaceuticals

Active, not recruiting

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Diabetic Macular Edema (DME) | Neovascular Age-Related Macular Degeneration (nAMD)

United States
Fondazione Poliambulanza Istituto Ospedaliero

Completed

Prevention of Hypoglycaemia by Oral 40% Destrogel

Hypoglycaemia Neonatal

Italy
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland
University of Athens

Completed

Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion (INTRAMED-CRVO)

Retinal Vein Occlusion | Vascular Occlusive Disease
Novartis Pharmaceuticals

Completed

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (TIDE AMD)

Wet Age-Related Macular Degeneration

Germany
Arshad Khanani
Genentech, Inc.

Completed

Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME

Diabetic Macular Edema

United States
Novartis Pharmaceuticals

Completed

A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (RIVAL)

Age-Related Macular Degeneration

Australia
Regeneron Pharmaceuticals

Not yet recruiting

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (SPECTRUM-US)

Visual Impairment | Diabetic Macular Edema (DME) | Neovascular Age-related Macular Degeneration (nAMD) | Wet Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)

Central Retinal Vein Occlusion

China, Czechia, Germany, Russian Federation, Turkey, United States, Australia, Canada, Spain, United Kingdom, Thailand, Israel, Netherlands, Italy, Hungary, France, Greece, Puerto Rico, Malaysia, Japan
Hospital Universitario Ramon y Cajal

Terminated

Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01) (COVITOZ-01)

Covid19

Spain
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

Branch Retinal Vein Occlusion

China, Austria, Czechia, Russian Federation, Taiwan, United Kingdom, Canada, Japan, United States, France, Israel, Germany, Italy, Hong Kong, Spain, Denmark, Slovakia, Puerto Rico, Switzerland
Northern California Retina Vitreous Associates
Regeneron Pharmaceuticals

Completed

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions (NEWTON)

Macular Edema With Central Retinal Vein Occlusions

United States
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

Neovascular Age-related Macular Degeneration

United States, Puerto Rico
Centre Hospitalier Universitaire, Amiens

Completed

Serratus Plain Block Versus Paravertebral Block Versus Serratus Plain Block and Paravertebral Block for Postoperative Pain Following Thoracoscopic Surgery (thoracoscopic)

Pain, Postoperative | Anesthesia, Local

France
Maimónides Biomedical Research Institute of Córdoba
Consejería de Salud y Familias - Junta de Andalucía; Red Andaluza de Ensayos...

Completed

Clinical Trial of Sarilumab in Adults With COVID-19 (SARICOR)

SARS-CoV 2 | SARS

Spain
Southeast Retina Center, Georgia

Unknown

Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH (LASERLESS)

Proliferative Diabetic Retinopathy

United States
Richever Enterprise Co., Ltd.

Unknown

Clinical Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®)

Galactose Single Point (GSP), Residual Liver Function
Sunnybrook Health Sciences Centre

Unknown

PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept (PRaCTICAL)

Age Related Macular Degeneration | Central Serous Chorioretinopathy | Idiopathic Poplypoidal Choroidal Vasculopathy

Canada
Unity Health Toronto

Unknown

Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study

Diabetic Macular Edema
Bayer

Recruiting

An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)

Preterm Infants | Retinopathy of Prematurity

United Kingdom
Chengdu Kanghong Biotech Co., Ltd.

Terminated

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

Neovascular Age-related Macular Degeneration

United States, Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Germany, Hong Kong, Lithuania, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Singapore, Spain, Switzerland, Taiwan
Chengdu Kanghong Biotech Co., Ltd.

Terminated

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)

Neovascular Age-related Macular Degeneration

United States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom
Centro Hospitalar do Porto

Completed

Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema (DEVITRA)

Diabetic Macular Edema

Portugal
Boston Scientific Corporation

Completed

COMFORT: A Multicenter, Open-label, Randomized, Crossover Study (COMFORT)

Varicose Veins

United States
Northern California Retina Vitreous Associates
Regeneron Pharmaceuticals

Completed

The Endurance 1 Trial (Endurance)

Diabetic Macular Edema
Alcon Research

Completed

Efficacy and Safety Study of ESBA1008 Versus EYLEA®

Exudative Age-Related Macular Degeneration
Alcon Research

Completed

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma
Jadran Galenski laboratorij d.d.

Completed

Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL

Primary Open Angle Glaucoma of Both Eyes

Russian Federation
Alcon Research

Completed

Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health

Ocular Hypertension | Open Angle Glaucoma
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

Migraine Disorders

Japan
Hospital Hietzing

Completed

Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser

Diabetic Retinal Edema

Austria
Tennessee Retina
Regeneron Pharmaceuticals

Unknown

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept (TRISTAR)

Neovascular Age-related Macular Degeneration

United States
Retina-Vitreous Associates Medical Group

Completed

Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema (Endurance3)

Clinically Significant Diabetic Macular Edema

Search clinical trials for: Aflibercept 40 MG/ML Intraocular Solution [EYLEA]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations